Partner with us

Healthy genes can be switched off by a few methyl groups in the wrong place.

Aptadir is a Milan biotech developing DiRs, RNA inhibitors designed to switch silenced genes back on. Scroll to watch one at work, or drag the helix.

  1. A gene falls silent

    DNMT1 places methyl groups on the gene's promoter. The DNA is intact, yet the cell stops reading it.

  2. A DiR binds DNMT1

    Our RNA inhibitor docks onto the enzyme. A captaDiR carries a gene-specific sequence, so it acts at one locus only.

  3. The methyl marks lift

    With DNMT1 held back, methylation at the target falls with each round of cell division.

  4. The gene is read again

    Transcription resumes and the protein returns. In Fragile X Syndrome that gene is FMR1, the target of our lead CAP1-FMR1.

    Read about the platform

Our mission

Some diseases are caused by healthy genes that aberrant DNA methylation has switched off. We are turning a discovery published in Nature into medicines that address that cause, rather than managing its symptoms.

The science was developed at Beth Israel Deaconess Medical Center, the Italian National Research Council, the Cancer Science Institute of Singapore and City of Hope.

One RNA platform, built for global or gene-specific demethylation

aptaDiR

Modified short RNA oligonucleotides that sequester DNMT1, the enzyme behind aberrant methylation, without the cell toxicity seen with commercially available hypomethylating drugs.

How aptaDiR works

captaDiR

An aptaDiR fused with a gene-specific sequence, so demethylation happens only at the targeted locus. This is the basis of our lead programme in Fragile X Syndrome.

See the pipeline

Pipeline

We are a preclinical company. The seed round funds CAP1-FMR1 towards clinical development and additional programmes in genetic disorders and oncology.

IndicationProgrammeDiscoveryPreclinicalPhase 1Phase 2
Fragile X SyndromeCAP1-FMR1 Lead
Myelodysplastic neoplasmsOncologyStage not disclosed
Non-small cell lung cancerOncologyStage not disclosed
Metabolic disordersNot disclosedStage not disclosed

A seed round to take DiRs towards the clinic

In September 2026 Aptadir closed a €40 million seed round, the largest biotech seed financing in Italy and one of the largest in Europe.

Read the announcement

Backed by

  • 4BIO Capital
  • Extend
  • CDP Venture Capital
  • XGEN Venture
  • CE-Ventures

“With the backing of our investors, we now have the opportunity to develop a pipeline of drug candidates with the potential to restore genetic pathways that, for decades, have been considered irreversibly silenced.”

Giovanni Amabile, PhDFounder, CEO and Executive Chairman
Portrait of Giovanni Amabile

Scientific founders

Meet the full team
Portrait of Annalisa Di Ruscio

Annalisa Di Ruscio, MD, PhD

RNA biology and DNA methylation in blood cancers

Portrait of Vittorio De Franciscis

Vittorio De Franciscis, PhD

Over 35 years in aptamer technology

Portrait of Daniel G. Tenen

Daniel G. Tenen, MD

Gene regulation in normal and cancer cells

Portrait of Marcin Kortylewski

Marcin Kortylewski, PhD

Oligonucleotide therapeutics

Partners and investors

For partnering, licensing or investment conversations, write to the team in Milan.

Contact the team

Researchers

The platform builds on peer-reviewed work in Nature, Nature Communications and Science Advances.

Read the publications

Read the latest

Aptadir raises €40 million in Italy's largest biotech seed round

Read on tech.eu

Aptadir Therapeutics press release

Download the PDF